Can Pre-transplant Platelet Count Predict Acute Graft-versus-host Disease and Overall Survival in Allogeneic Hematopoietic Stem Cell Transplantation?

Simple item page
AuthorMahmoud Dehghani Ghorbien
AuthorElham Roshandelen
AuthorMaryam Nikoonezhaden
AuthorAnahita Saeedien
AuthorMahshid Vafajooen
AuthorAbbas Hajifathalien
AuthorMahshid Mehdizadehen
OrcidElham Roshandel [0000-0002-3698-4342]en
OrcidAbbas Hajifathali [0000-0002-2711-9277]en
OrcidMahshid Mehdizadeh [0000-0002-8937-5495]en
Issued Date2025-12-31en
AbstractBackground: Thrombocytopenia is a primary consequence of chemotherapy and radiotherapy in leukemia, leading to the need for blood product transfusions in patients undergoing hematopoietic stem cell transplantation (HSCT). Although blood product transfusion plays a pivotal role in the supportive care of HSCT patients, multiple transfusions can lead to alloreactive complications. Objectives: In this study, we assessed the association of pre-transplant platelet count and blood product transfusions with acute graft-versus-host disease (aGVHD), organ failure, and overall survival (OS) as outcomes following HSCT. Methods: This retrospective study was conducted on clinical records of 184 patients who underwent allogeneic HSCT (allo-HSCT). Platelet counts on admission and on the day of transplantation were analyzed using ROC analysis to determine cut-off values. The associations between platelet count, packed red cell volume, and platelet transfusions with aGVHD, organ failure, and OS were examined. Results: A platelet count >134.5×103/µL on the day of transplantation was associated with a 56% reduction in the risk of mortality (P = 0.045). An increased number of random donor platelet transfusions had a significant adverse effect on aGVHD incidence and 5-year OS (P = 0.228, 0.035). The number of packed cell units transfused was significantly associated with both increased odds of aGVHD incidence and a higher risk of mortality (P = 0.041, < 0.001). Conclusions: Pre-transplantation platelet count and blood product transfusion are associated with a higher risk of aGVHD and reduced 5-year OS following allo-HSCT. Therefore, implementing strategies to minimize blood product transfusion may help reduce the incidence of aGVHD and improve overall survival.en
DOIhttps://doi.org/10.5812/ijcm-138172en
KeywordPlateleten
KeywordHematopoietic Stem Cell Transplantationen
KeywordGraft-versus-host Diseaseen
KeywordOverall Survivalen
KeywordBlood Product Transfusionen
PublisherBrieflandsen
TitleCan Pre-transplant Platelet Count Predict Acute Graft-versus-host Disease and Overall Survival in Allogeneic Hematopoietic Stem Cell Transplantation?en
TypeResearch Articleen

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijcm-18-1-138172-publish-pdf.pdf
Size:
292.8 KB
Format:
Adobe Portable Document Format
Description:
Article/s PDF
Download

Collections

International Journal of Cancer Management